Validated Model of Idiopathic Pulmonary Fibrosis/Lung Injury
Bleomycin is a chemotherapeutic agent used to treat cancers such as Hodgkins lymphoma. One of the side effects is pulmonary toxicity, which can be life threatening in approximately 10% of patients.
The mechanism of bleomycin-induced lung injury includes oxidative damage via oxidant-mediated DNA breaks, causing inflammatory reactions in the lungs.
Bleomycin has also been used to induce lung injury in rodents for basic research into pulmonary fibrosis for over a decade. At MD Biosciences, we have refined the oral aspiration administration to allow for more even distribution of disease throughout both right and left lungs, making bleomycin-induced injury in mice a reliable model for research. This is a great model for studying idiopathic pulmonary fibrosis (IPF).
Available Bleomycin Study Readouts:
Figure 1. Late Stage Histology from Control & Bleomycin-treated Mouse Lung
Other Fibrosis Animal Models
Contact us to learn more about our fibrosis capabilities and to discuss study design!